208 related articles for article (PubMed ID: 18663709)
1. Design and synthesis of aryl ether inhibitors of the Bacillus anthracis enoyl-ACP reductase.
Tipparaju SK; Mulhearn DC; Klein GM; Chen Y; Tapadar S; Bishop MH; Yang S; Chen J; Ghassemi M; Santarsiero BD; Cook JL; Johlfs M; Mesecar AD; Johnson ME; Kozikowski AP
ChemMedChem; 2008 Aug; 3(8):1250-68. PubMed ID: 18663709
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of 2-pyridones as novel inhibitors of the Bacillus anthracis enoyl-ACP reductase.
Tipparaju SK; Joyasawal S; Forrester S; Mulhearn DC; Pegan S; Johnson ME; Mesecar AD; Kozikowski AP
Bioorg Med Chem Lett; 2008 Jun; 18(12):3565-9. PubMed ID: 18499454
[TBL] [Abstract][Full Text] [Related]
3. Structural and biological evaluation of a novel series of benzimidazole inhibitors of Francisella tularensis enoyl-ACP reductase (FabI).
Mehboob S; Song J; Hevener KE; Su PC; Boci T; Brubaker L; Truong L; Mistry T; Deng J; Cook JL; Santarsiero BD; Ghosh AK; Johnson ME
Bioorg Med Chem Lett; 2015 Mar; 25(6):1292-6. PubMed ID: 25677657
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a potent enoyl-acyl carrier protein reductase (FabI) inhibitor suitable for antistaphylococcal agent.
Kim YG; Seo JH; Kwak JH; Shin KJ
Bioorg Med Chem Lett; 2015 Oct; 25(20):4481-6. PubMed ID: 26343826
[TBL] [Abstract][Full Text] [Related]
5. Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.
Seefeld MA; Miller WH; Newlander KA; Burgess WJ; DeWolf WE; Elkins PA; Head MS; Jakas DR; Janson CA; Keller PM; Manley PJ; Moore TD; Payne DJ; Pearson S; Polizzi BJ; Qiu X; Rittenhouse SF; Uzinskas IN; Wallis NG; Huffman WF
J Med Chem; 2003 Apr; 46(9):1627-35. PubMed ID: 12699381
[TBL] [Abstract][Full Text] [Related]
6. Rational design of broad spectrum antibacterial activity based on a clinically relevant enoyl-acyl carrier protein (ACP) reductase inhibitor.
Schiebel J; Chang A; Shah S; Lu Y; Liu L; Pan P; Hirschbeck MW; Tareilus M; Eltschkner S; Yu W; Cummings JE; Knudson SE; Bommineni GR; Walker SG; Slayden RA; Sotriffer CA; Tonge PJ; Kisker C
J Biol Chem; 2014 Jun; 289(23):15987-6005. PubMed ID: 24739388
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 4-Pyridone derivatives as specific inhibitors of enoyl-acyl carrier protein reductase (FabI) with antibacterial activity against Staphylococcus aureus.
Takahata S; Iida M; Yoshida T; Kumura K; Kitagawa H; Hoshiko S
J Antibiot (Tokyo); 2007 Feb; 60(2):123-8. PubMed ID: 17420562
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.
Lu H; Tonge PJ
Acc Chem Res; 2008 Jan; 41(1):11-20. PubMed ID: 18193820
[TBL] [Abstract][Full Text] [Related]
9. FabI (enoyl acyl carrier protein reductase) - A potential broad spectrum therapeutic target and its inhibitors.
Rana P; Ghouse SM; Akunuri R; Madhavi YV; Chopra S; Nanduri S
Eur J Med Chem; 2020 Dec; 208():112757. PubMed ID: 32883635
[TBL] [Abstract][Full Text] [Related]
10. Ligand- and Structure-Based Approaches of Escherichia coli FabI Inhibition by Triclosan Derivatives: From Chemical Similarity to Protein Dynamics Influence.
Kronenberger T; de Oliveira Fernades P; Drumond Franco I; Poso A; Gonçalves Maltarollo V
ChemMedChem; 2019 Dec; 14(23):1995-2004. PubMed ID: 31670463
[TBL] [Abstract][Full Text] [Related]
11. Selectivity of Pyridone- and Diphenyl Ether-Based Inhibitors for the Yersinia pestis FabV Enoyl-ACP Reductase.
Neckles C; Pschibul A; Lai CT; Hirschbeck M; Kuper J; Davoodi S; Zou J; Liu N; Pan P; Shah S; Daryaee F; Bommineni GR; Lai C; Simmerling C; Kisker C; Tonge PJ
Biochemistry; 2016 May; 55(21):2992-3006. PubMed ID: 27136302
[TBL] [Abstract][Full Text] [Related]
12. Synthetic and crystallographic studies of a new inhibitor series targeting Bacillus anthracis dihydrofolate reductase.
Beierlein JM; Frey KM; Bolstad DB; Pelphrey PM; Joska TM; Smith AE; Priestley ND; Wright DL; Anderson AC
J Med Chem; 2008 Dec; 51(23):7532-40. PubMed ID: 19007108
[TBL] [Abstract][Full Text] [Related]
13. Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI).
Miller WH; Seefeld MA; Newlander KA; Uzinskas IN; Burgess WJ; Heerding DA; Yuan CC; Head MS; Payne DJ; Rittenhouse SF; Moore TD; Pearson SC; Berry V; DeWolf WE; Keller PM; Polizzi BJ; Qiu X; Janson CA; Huffman WF
J Med Chem; 2002 Jul; 45(15):3246-56. PubMed ID: 12109908
[TBL] [Abstract][Full Text] [Related]
14. Modification of triclosan scaffold in search of improved inhibitors for enoyl-acyl carrier protein (ACP) reductase in Toxoplasma gondii.
Stec J; Fomovska A; Afanador GA; Muench SP; Zhou Y; Lai BS; El Bissati K; Hickman MR; Lee PJ; Leed SE; Auschwitz JM; Sommervile C; Woods S; Roberts CW; Rice D; Prigge ST; McLeod R; Kozikowski AP
ChemMedChem; 2013 Jul; 8(7):1138-60. PubMed ID: 23776166
[TBL] [Abstract][Full Text] [Related]
15. Time-dependent diaryl ether inhibitors of InhA: structure-activity relationship studies of enzyme inhibition, antibacterial activity, and in vivo efficacy.
Pan P; Knudson SE; Bommineni GR; Li HJ; Lai CT; Liu N; Garcia-Diaz M; Simmerling C; Patil SS; Slayden RA; Tonge PJ
ChemMedChem; 2014 Apr; 9(4):776-91. PubMed ID: 24616444
[TBL] [Abstract][Full Text] [Related]
16. Verrulactone C with an unprecedented dispiro skeleton, a new inhibitor of Staphylococcus aureus enoyl-ACP reductase, from Penicillium verruculosum F375.
Kim N; Sohn MJ; Koshino H; Kim EH; Kim WG
Bioorg Med Chem Lett; 2014 Jan; 24(1):83-6. PubMed ID: 24332629
[TBL] [Abstract][Full Text] [Related]
17. A novel series of enoyl reductase inhibitors targeting the ESKAPE pathogens, Staphylococcus aureus and Acinetobacter baumannii.
Kwon J; Mistry T; Ren J; Johnson ME; Mehboob S
Bioorg Med Chem; 2018 Jan; 26(1):65-76. PubMed ID: 29162308
[TBL] [Abstract][Full Text] [Related]
18. Virtual screening of antibacterial compounds by similarity search of Enoyl-ACP reductase (FabI) inhibitors.
Asse Junior LR; Kronenberger T; Magalhães Serafim MS; Sousa YV; Franco ID; Valli M; Silva Bolzani VD; Monteiro GC; Bruno Prates JL; Kroon EG; Fernandes Mota BE; Santos Ferreira DD; de Oliveira RB; Maltarollo VG
Future Med Chem; 2020 Jan; 12(1):51-68. PubMed ID: 31729258
[No Abstract] [Full Text] [Related]
19. Structural insights into the dimer-tetramer transition of FabI from Bacillus anthracis.
Kim HT; Kim S; Na BK; Chung J; Hwang E; Hwang KY
Biochem Biophys Res Commun; 2017 Nov; 493(1):28-33. PubMed ID: 28935372
[TBL] [Abstract][Full Text] [Related]
20. Slow-onset inhibition of the FabI enoyl reductase from francisella tularensis: residence time and in vivo activity.
Lu H; England K; am Ende C; Truglio JJ; Luckner S; Reddy BG; Marlenee NL; Knudson SE; Knudson DL; Bowen RA; Kisker C; Slayden RA; Tonge PJ
ACS Chem Biol; 2009 Mar; 4(3):221-31. PubMed ID: 19206187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
